SQZ Biotechnologies Form 4 / AMY W SCHULMAN ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

SCHULMAN AMY W

(Last)

(First)

(Middle)

C/O SQZ BIOTECHNOLOGIES COMPANY

200 ARSENAL YARDS BLVD, SUITE 210

(Street)

WATERTOWN

02472

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
SQZ Biotechnologies Co [ SQZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/03/2020		C		22,204	A	⁽¹⁾	190,684	D
Common Stock	11/03/2020		C		161,994	A	⁽¹⁾	161,994	I	See footnotes⁽²⁾⁽³⁾
Common Stock	11/03/2020		C		2,315,652	A	⁽¹⁾	2,315,652	I	See footnotes⁽³⁾⁽⁴⁾
Common Stock	11/03/2020		C		275,860	A	⁽¹⁾	275,860	I	See footnote⁽⁵⁾
Common Stock	11/03/2020		P		16,346	A	$16	178,340	I	See footnotes⁽²⁾⁽³⁾
Common Stock	11/03/2020		P		233,654	A	$16	2,549,306	I	See footnotes⁽³⁾⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series A Convertible Preferred Stock	⁽¹⁾	11/03/2020		C			28,863	⁽¹⁾	⁽¹⁾	Common Stock	30,392	⁽¹⁾	0	I	See footnotes⁽²⁾⁽³⁾
Series A Convertible Preferred Stock	⁽¹⁾	11/03/2020		C			412,608	⁽¹⁾	⁽¹⁾	Common Stock	434,476	⁽¹⁾	0	I	See footnotes⁽³⁾⁽⁴⁾
Series B Convertible Preferred Stock	⁽¹⁾	11/03/2020		C			56,462	⁽¹⁾	⁽¹⁾	Common Stock	59,454	⁽¹⁾	0	I	See footnotes⁽²⁾⁽³⁾
Series B Convertible Preferred Stock	⁽¹⁾	11/03/2020		C			807,096	⁽¹⁾	⁽¹⁾	Common Stock	849,872	⁽¹⁾	0	I	See footnotes⁽³⁾⁽⁴⁾
Series C Convertible Preferred Stock	⁽¹⁾	11/03/2020		C			44,120	⁽¹⁾	⁽¹⁾	Common Stock	46,458	⁽¹⁾	0	I	See footnotes⁽²⁾⁽³⁾
Series C Convertible Preferred Stock	⁽¹⁾	11/03/2020		C			630,672	⁽¹⁾	⁽¹⁾	Common Stock	664,097	⁽¹⁾	0	I	See footnotes⁽³⁾⁽⁴⁾
Series C Convertible Preferred Stock	⁽¹⁾	11/03/2020		C			168,698	⁽¹⁾	⁽¹⁾	Common Stock	177,638	⁽¹⁾	0	I	See footnote⁽⁵⁾
Series C Convertible Preferred Stock	⁽¹⁾	11/03/2020		C			21,087	⁽¹⁾	⁽¹⁾	Common Stock	22,204	⁽¹⁾	0	D
Series D Convertible Preferred Stock	⁽¹⁾	11/03/2020		C			24,396	⁽¹⁾	⁽¹⁾	Common Stock	25,690	⁽¹⁾	0	I	See footnotes⁽²⁾⁽³⁾
Series D Convertible Preferred Stock	⁽¹⁾	11/03/2020		C			348,725	⁽¹⁾	⁽¹⁾	Common Stock	367,207	⁽¹⁾	0	I	See footnotes⁽³⁾⁽⁴⁾
Series D Convertible Preferred Stock	⁽¹⁾	11/03/2020		C			93,279	⁽¹⁾	⁽¹⁾	Common Stock	98,222	⁽¹⁾	0	I	See footnote⁽⁵⁾

Explanation of Responses:

1. Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.

2. These shares are held of record by Polaris Entrepreneurs' Fund VII, L.P. ("EF VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of EF VII. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren (the "Managing Members") are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII.

3. Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

4. These shares are held of record by Polaris Partners VII, L.P. ("PP VII"). PMC VII is the general partner of PP VII. The Managing Members are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII.

5. These shares are held of record by LS Polaris Innovation Fund, L.P. ("LSPIF"). LS Polaris Innovation Fund GP, L.L.C. ("LSPIF GP") is the general partner of LSPIF. The Reporting Person is the sole managing member of LSPIF GP. Each of LSPIF GP and the Reporting Person may be deemed to have sole investment, voting and dispositive power over these shares. LSPIF GP and the Reporting Person disclaim beneficial ownership of the shares held by LSPIF and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Remarks:

	/s/ Lawrence Knopf, Attorney-in-Fact for Amy W. Schulman	11/03/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SQZ Biotechnologies (SQZB) Form 4SQZ Biotechnologies / AMY W SCHULMAN ownership change